A Clinical study to see the effect of Unani medicine Habb e Surfa in Surfa Yabis (Cough)

Phase 2

Recruiting

• Conditions: Cough, Surfa Yabis (Cough),

• Registration Number: CTRI/2018/10/016176
• Lead Sponsor: Central Council for Research in Unani Medicine

Brief Summary

| |

| --- |

|This study is designed as a multicentric open trial in patients with **Surfa YÄbis (Dry Cough)** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically on Baseline and of treatment.  This includes subjective assessment of general well being and physical examination . The total duration of treatment will be two weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

Composition of*Habb e Surfa*The Ingredients of the formulation as mentioned in the *National Formulary of Unani Medicine Part I* are as under:

| | | |

| --- | --- | --- |

|**S. No.**

**Ingredients**

**Quantity**

|

*Asl-us-Soos*

20 g

|

*Tukhm-e-Khubbazi*

20 g

|

*Maghz-Tukhm-e-Kaddu Shireen*

20 g

|

*Samagh-e-Arabi Biryan*

15 g

|

*Kateera*

15 g

|

*Nishasta-e-Gandum*

15 g

|

*Zafran*

5 g

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03-24
• Last Update Posted: 2018-04-12

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients of either sex in the age group of 18-60 2.
• Surfa YÄbis (Dry Cough) of < 3 weeks duration.

Exclusion Criteria

• Upper respiratory tract Infections having productive cough.
• Lower Respiratory Tract Infections (LRI or LRTI) including pneumonia, lung abscess, and acute bronchitis.
• 3.Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema.
• Bronchiectasis, pulmonary tuberculosis, pulmonary oedema, interstitial pulmonary fibrosis 5.
• Tumours of larynx, bronchi, and lungs 6.
• High Grade Fever > 101oF 7.
• Diabetes Mellitus, Hypertension 9.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Surfa Yabis (Cough)	2 WEEKS

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	at baseline and at the end of treatment

Trial Locations

Locations (3)

Clinical Research Unit; 🇮🇳 Bhopal, MADHYA PRADESH, India

Clinical Research Unit, Burhanpur; 🇮🇳 Nimar, MADHYA PRADESH, India

Regional Research Center; 🇮🇳 Allahabad, UTTAR PRADESH, India

Clinical Research Unit

🇮🇳Bhopal, MADHYA PRADESH, India

Dr Amir Faisal

Principal investigator

09827082483

crubpl.incharge@gmail.com